In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ACADIA Pharmaceuticals Inc.

https://www.acadia-pharm.com/

Latest From ACADIA Pharmaceuticals Inc.

Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas

Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.

Deals Business Strategies

Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.

Commercial Clinical Trials

Teva Sees COVID Sales Correction

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Sales & Earnings Strategy

Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Receptor Technologies
UsernamePublicRestriction

Register